Derek Small

Derek Small, co-founder and CEO of Syndeo, discusses groundbreaking advances in treating neurological disorders, including the Boost platform for drug development. He highlights the critical role of synaptic function in mental health and the promise of event-driven pharmacology. The conversation also delves into the potential of psychedelics for therapeutic use and the innovative drug Zalquistinol, currently in trials for depression and Alzheimer's. Small advocates for destigmatizing mental health while emphasizing the need for targeted therapies and innovative strategies in drug discovery.